Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1993 Jan;52(1):74–80. doi: 10.1136/ard.52.1.74

That oestrogen replacement for osteoporosis prevention should no longer be a bone of contention.

T G Palferman 1
PMCID: PMC1004962  PMID: 8427521

Full text

PDF
74

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abdalla H. I., Hart D. M., Lindsay R., Leggate I., Hooke A. Prevention of bone mineral loss in postmenopausal women by norethisterone. Obstet Gynecol. 1985 Dec;66(6):789–792. [PubMed] [Google Scholar]
  2. Abdalla H. I., Hart D. M., Lindsay R., Leggate I., Hooke A. Prevention of bone mineral loss in postmenopausal women by norethisterone. Obstet Gynecol. 1985 Dec;66(6):789–792. [PubMed] [Google Scholar]
  3. Aloia J. F., Cohn S. H., Vaswani A., Yeh J. K., Yuen K., Ellis K. Risk factors for postmenopausal osteoporosis. Am J Med. 1985 Jan;78(1):95–100. doi: 10.1016/0002-9343(85)90468-1. [DOI] [PubMed] [Google Scholar]
  4. Anderson T. J., Ferguson D. J., Raab G. M. Cell turnover in the "resting" human breast: influence of parity, contraceptive pill, age and laterality. Br J Cancer. 1982 Sep;46(3):376–382. doi: 10.1038/bjc.1982.213. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Barlow D. H., Abdalla H. I., Roberts A. D., Al Azzawi F., Leggate I., Hart D. M. Long-term hormone implant therapy--hormonal and clinical effects. Obstet Gynecol. 1986 Mar;67(3):321–325. [PubMed] [Google Scholar]
  6. Barlow D. H., Grosset K. A., Hart H., Hart D. M. A study of the experience of Glasgow women in the climacteric years. Br J Obstet Gynaecol. 1989 Oct;96(10):1192–1197. doi: 10.1111/j.1471-0528.1989.tb03195.x. [DOI] [PubMed] [Google Scholar]
  7. Bergkvist L., Adami H. O., Persson I., Hoover R., Schairer C. The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med. 1989 Aug 3;321(5):293–297. doi: 10.1056/NEJM198908033210505. [DOI] [PubMed] [Google Scholar]
  8. Bijvoet O. L. Consensus osteoporose. Ned Tijdschr Geneeskd. 1986 Mar 29;130(13):584–590. [PubMed] [Google Scholar]
  9. Bush T. L., Barrett-Connor E., Cowan L. D., Criqui M. H., Wallace R. B., Suchindran C. M., Tyroler H. A., Rifkind B. M. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation. 1987 Jun;75(6):1102–1109. doi: 10.1161/01.cir.75.6.1102. [DOI] [PubMed] [Google Scholar]
  10. Christensen M. S., Hagen C., Christiansen C., Transbøl I. Dose-response evaluation of cyclic estrogen/gestagen in postmenopausal women: placebo-controlled trial of its gynecologic and metabolic actions. Am J Obstet Gynecol. 1982 Dec 15;144(8):873–879. doi: 10.1016/0002-9378(82)90176-4. [DOI] [PubMed] [Google Scholar]
  11. Christiansen C., Christensen M. S., McNair P., Hagen C., Stocklund K. E., Transbøl I. Prevention of early postmenopausal bone loss: controlled 2-year study in 315 normal females. Eur J Clin Invest. 1980 Aug;10(4):273–279. doi: 10.1111/j.1365-2362.1980.tb00033.x. [DOI] [PubMed] [Google Scholar]
  12. Christiansen C., Riis B. J., Rødbro P. Prediction of rapid bone loss in postmenopausal women. Lancet. 1987 May 16;1(8542):1105–1108. doi: 10.1016/s0140-6736(87)91671-0. [DOI] [PubMed] [Google Scholar]
  13. Chu J., Schweid A. I., Weiss N. S. Survival among women with endometrial cancer: a comparison of estrogen users and nonusers. Am J Obstet Gynecol. 1982 Jul 1;143(5):569–573. doi: 10.1016/0002-9378(82)90549-x. [DOI] [PubMed] [Google Scholar]
  14. Cramer D. W., Devesa S. S., Welch W. R. Trends in the incidence of endometrioid and clear cell cancers of the ovary in the United States. Am J Epidemiol. 1981 Aug;114(2):201–208. doi: 10.1093/oxfordjournals.aje.a113183. [DOI] [PubMed] [Google Scholar]
  15. Cummings S. R., Kelsey J. L., Nevitt M. C., O'Dowd K. J. Epidemiology of osteoporosis and osteoporotic fractures. Epidemiol Rev. 1985;7:178–208. doi: 10.1093/oxfordjournals.epirev.a036281. [DOI] [PubMed] [Google Scholar]
  16. Cundy T., Evans M., Roberts H., Wattie D., Ames R., Reid I. R. Bone density in women receiving depot medroxyprogesterone acetate for contraception. BMJ. 1991 Jul 6;303(6793):13–16. doi: 10.1136/bmj.303.6793.13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Davidson B. J., Riggs B. L., Wahner H. W., Judd H. L. Endogenous cortisol and sex steroids in patients with osteoporotic spinal fractures. Obstet Gynecol. 1983 Mar;61(3):275–278. [PubMed] [Google Scholar]
  18. Dillard T. A., Berg B. W., Rajagopal K. R., Dooley J. W., Mehm W. J. Hypoxemia during air travel in patients with chronic obstructive pulmonary disease. Ann Intern Med. 1989 Sep 1;111(5):362–367. doi: 10.7326/0003-4819-111-5-362. [DOI] [PubMed] [Google Scholar]
  19. Draper J., Roland M. Perimenopausal women's views on taking hormone replacement therapy to prevent osteoporosis. BMJ. 1990 Mar 24;300(6727):786–788. doi: 10.1136/bmj.300.6727.786. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Elders P. J., Netelenbos J. C., Lips P., Khoe E., van Ginkel F. C., Hulshof K. F., van der Stelt P. F. Perimenopausal bone mass and risk factors. Bone Miner. 1989 Nov;7(3):289–299. doi: 10.1016/0169-6009(89)90085-8. [DOI] [PubMed] [Google Scholar]
  21. Eriksson M., Berglund L., Rudling M., Henriksson P., Angelin B. Effects of estrogen on low density lipoprotein metabolism in males. Short-term and long-term studies during hormonal treatment of prostatic carcinoma. J Clin Invest. 1989 Sep;84(3):802–810. doi: 10.1172/JCI114239. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Ettinger B., Genant H. K., Cann C. E. Long-term estrogen replacement therapy prevents bone loss and fractures. Ann Intern Med. 1985 Mar;102(3):319–324. doi: 10.7326/0003-4819-102-3-319. [DOI] [PubMed] [Google Scholar]
  23. Evans J. G., Prudham D., Wandless I. A prospective study of fractured proximal femur: incidence and outcome. Public Health. 1979 Jul;93(4):235–241. doi: 10.1016/s0033-3506(79)80036-0. [DOI] [PubMed] [Google Scholar]
  24. Feyen J. H., Raisz L. G. Prostaglandin production by calvariae from sham operated and oophorectomized rats: effect of 17 beta-estradiol in vivo. Endocrinology. 1987 Aug;121(2):819–821. doi: 10.1210/endo-121-2-819. [DOI] [PubMed] [Google Scholar]
  25. Fukayama S., Tashjian A. H., Jr Direct modulation by estradiol of the response of human bone cells (SaOS-2) to human parathyroid hormone (PTH) and PTH-related protein. Endocrinology. 1989 Jan;124(1):397–401. doi: 10.1210/endo-124-1-397. [DOI] [PubMed] [Google Scholar]
  26. Gallagher J. C., Kable W. T., Goldgar D. Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen. Am J Med. 1991 Feb;90(2):171–178. [PubMed] [Google Scholar]
  27. Godsland I. F., Wynn V., Crook D., Miller N. E. Sex, plasma lipoproteins, and atherosclerosis: prevailing assumptions and outstanding questions. Am Heart J. 1987 Dec;114(6):1467–1503. doi: 10.1016/0002-8703(87)90552-7. [DOI] [PubMed] [Google Scholar]
  28. Gordon T., Kannel W. B., Hjortland M. C., McNamara P. M. Menopause and coronary heart disease. The Framingham Study. Ann Intern Med. 1978 Aug;89(2):157–161. doi: 10.7326/0003-4819-89-2-157. [DOI] [PubMed] [Google Scholar]
  29. Gärdsell P., Johnell O., Nilsson B. E. Predicting fractures in women by using forearm bone densitometry. Calcif Tissue Int. 1989 Apr;44(4):235–242. doi: 10.1007/BF02553757. [DOI] [PubMed] [Google Scholar]
  30. Hansen M. A., Overgaard K., Riis B. J., Christiansen C. Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 year study. BMJ. 1991 Oct 19;303(6808):961–964. doi: 10.1136/bmj.303.6808.961. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Hiatt R. A., Bawol R., Friedman G. D., Hoover R. Exogenous estrogen and breast cancer after bilateral oophorectomy. Cancer. 1984 Jul 1;54(1):139–144. doi: 10.1002/1097-0142(19840701)54:1<139::aid-cncr2820540128>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  32. Hirvonen E., Mälkönen M., Manninen V. Effects of different progestogens on lipoproteins during postmenopausal replacement therapy. N Engl J Med. 1981 Mar 5;304(10):560–563. doi: 10.1056/NEJM198103053041002. [DOI] [PubMed] [Google Scholar]
  33. Hoover R., Glass A., Finkle W. D., Azevedo D., Milne K. Conjugated estrogens and breast cancer risk in women. J Natl Cancer Inst. 1981 Oct;67(4):815–820. [PubMed] [Google Scholar]
  34. Horsman A., Gallagher J. C., Simpson M., Nordin B. E. Prospective trial of oestrogen and calcium in postmenopausal women. Br Med J. 1977 Sep 24;2(6090):789–792. doi: 10.1136/bmj.2.6090.789. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Hunt K. Perceived value of treatment among a group of long-term users of hormone replacement therapy. J R Coll Gen Pract. 1988 Sep;38(314):398–401. [PMC free article] [PubMed] [Google Scholar]
  36. Hunt K., Vessey M., McPherson K., Coleman M. Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. Br J Obstet Gynaecol. 1987 Jul;94(7):620–635. doi: 10.1111/j.1471-0528.1987.tb03166.x. [DOI] [PubMed] [Google Scholar]
  37. Hutchinson T. A., Polansky S. M., Feinstein A. R. Post-menopausal oestrogens protect against fractures of hip and distal radius. A case-control study. Lancet. 1979 Oct 6;2(8145):705–709. doi: 10.1016/s0140-6736(79)90640-8. [DOI] [PubMed] [Google Scholar]
  38. Jensen G. F., Christiansen C., Boesen J., Hegedüs V., Transbøl I. Relationship between bone mineral content and frequency of postmenopausal fractures. Acta Med Scand. 1983;213(1):61–63. doi: 10.1111/j.0954-6820.1983.tb03691.x. [DOI] [PubMed] [Google Scholar]
  39. Jensen J., Nilas L., Christiansen C. Cyclic changes in serum cholesterol and lipoproteins following different doses of combined postmenopausal hormone replacement therapy. Br J Obstet Gynaecol. 1986 Jun;93(6):613–618. doi: 10.1111/j.1471-0528.1986.tb08035.x. [DOI] [PubMed] [Google Scholar]
  40. Jensen J., Riis B. J., Strøm V., Nilas L., Christiansen C. Long-term effects of percutaneous estrogens and oral progesterone on serum lipoproteins in postmenopausal women. Am J Obstet Gynecol. 1987 Jan;156(1):66–71. doi: 10.1016/0002-9378(87)90204-3. [DOI] [PubMed] [Google Scholar]
  41. Johnston C. C., Jr, Hui S. L., Witt R. M., Appledorn R., Baker R. S., Longcope C. Early menopausal changes in bone mass and sex steroids. J Clin Endocrinol Metab. 1985 Nov;61(5):905–911. doi: 10.1210/jcem-61-5-905. [DOI] [PubMed] [Google Scholar]
  42. Kaufman D. W., Miller D. R., Rosenberg L., Helmrich S. P., Stolley P., Schottenfeld D., Shapiro S. Noncontraceptive estrogen use and the risk of breast cancer. JAMA. 1984 Jul 6;252(1):63–67. [PubMed] [Google Scholar]
  43. Komm B. S., Terpening C. M., Benz D. J., Graeme K. A., Gallegos A., Korc M., Greene G. L., O'Malley B. W., Haussler M. R. Estrogen binding, receptor mRNA, and biologic response in osteoblast-like osteosarcoma cells. Science. 1988 Jul 1;241(4861):81–84. doi: 10.1126/science.3164526. [DOI] [PubMed] [Google Scholar]
  44. Komm B. S., Terpening C. M., Benz D. J., Graeme K. A., Gallegos A., Korc M., Greene G. L., O'Malley B. W., Haussler M. R. Estrogen binding, receptor mRNA, and biologic response in osteoblast-like osteosarcoma cells. Science. 1988 Jul 1;241(4861):81–84. doi: 10.1126/science.3164526. [DOI] [PubMed] [Google Scholar]
  45. Krølner B., Pors Nielsen S. Bone mineral content of the lumbar spine in normal and osteoporotic women: cross-sectional and longitudinal studies. Clin Sci (Lond) 1982 Mar;62(3):329–336. doi: 10.1042/cs0620329. [DOI] [PubMed] [Google Scholar]
  46. La Vecchia C., Liberati A., Franceschi S. Noncontraceptive estrogen use and the occurrence of ovarian cancer. J Natl Cancer Inst. 1982 Dec;69(6):1207–1207. [PubMed] [Google Scholar]
  47. Law M. R., Wald N. J., Meade T. W. Strategies for prevention of osteoporosis and hip fracture. BMJ. 1991 Aug 24;303(6800):453–459. doi: 10.1136/bmj.303.6800.453. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Lindsay R., Hart D. M., Aitken J. M., MacDonald E. B., Anderson J. B., Clarke A. C. Long-term prevention of postmenopausal osteoporosis by oestrogen. Evidence for an increased bone mass after delayed onset of oestrogen treatment. Lancet. 1976 May 15;1(7968):1038–1041. doi: 10.1016/s0140-6736(76)92217-0. [DOI] [PubMed] [Google Scholar]
  49. Lindsay R., Hart D. M., Clark D. M. The minimum effective dose of estrogen for prevention of postmenopausal bone loss. Obstet Gynecol. 1984 Jun;63(6):759–763. [PubMed] [Google Scholar]
  50. Lindsay R., Hart D. M., Kraszewski A. Prospective double-blind trial of synthetic steroid (Org OD 14) for preventing postmenopausal osteoporosis. Br Med J. 1980 May 17;280(6225):1207–1209. doi: 10.1136/bmj.280.6225.1207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Lobo R. A., McCormick W., Singer F., Roy S. Depo-medroxyprogesterone acetate compared with conjugated estrogens for the treatment of postmenopausal women. Obstet Gynecol. 1984 Jan;63(1):1–5. [PubMed] [Google Scholar]
  52. Magness R. R., Rosenfeld C. R. Local and systemic estradiol-17 beta: effects on uterine and systemic vasodilation. Am J Physiol. 1989 Apr;256(4 Pt 1):E536–E542. doi: 10.1152/ajpendo.1989.256.4.E536. [DOI] [PubMed] [Google Scholar]
  53. Mandel F. P., Davidson B. J., Erlik Y., Judd H. L., Meldrum D. R. Effects of progestins on bone metabolism in postmenopausal women. J Reprod Med. 1982 Aug;27(8 Suppl):511–514. [PubMed] [Google Scholar]
  54. Mazess R. B., Barden H. S. Bone densitometry for diagnosis and monitoring osteoporosis. Proc Soc Exp Biol Med. 1989 Jul;191(3):261–271. doi: 10.3181/00379727-191-42918. [DOI] [PubMed] [Google Scholar]
  55. Nachtigall L. E., Nachtigall R. H., Nachtigall R. D., Beckman E. M. Estrogen replacement therapy I: a 10-year prospective study in the relationship to osteoporosis. Obstet Gynecol. 1979 Mar;53(3):277–281. [PubMed] [Google Scholar]
  56. Nachtigall L. E., Nachtigall R. H., Nachtigall R. D., Beckman E. M. Estrogen replacement therapy II: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynecol. 1979 Jul;54(1):74–79. doi: 10.1097/00006250-197907000-00017. [DOI] [PubMed] [Google Scholar]
  57. Ottosson U. B., Johansson B. G., von Schoultz B. Subfractions of high-density lipoprotein cholesterol during estrogen replacement therapy: a comparison between progestogens and natural progesterone. Am J Obstet Gynecol. 1985 Mar 15;151(6):746–750. doi: 10.1016/0002-9378(85)90509-5. [DOI] [PubMed] [Google Scholar]
  58. Pacifici R., Rifas L., Teitelbaum S., Slatopolsky E., McCracken R., Bergfeld M., Lee W., Avioli L. V., Peck W. A. Spontaneous release of interleukin 1 from human blood monocytes reflects bone formation in idiopathic osteoporosis. Proc Natl Acad Sci U S A. 1987 Jul;84(13):4616–4620. doi: 10.1073/pnas.84.13.4616. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Padwick M. L., Pryse-Davies J., Whitehead M. I. A simple method for determining the optimal dosage of progestin in postmenopausal women receiving estrogens. N Engl J Med. 1986 Oct 9;315(15):930–934. doi: 10.1056/NEJM198610093151504. [DOI] [PubMed] [Google Scholar]
  60. Paganini-Hill A., Ross R. K., Gerkins V. R., Henderson B. E., Arthur M., Mack T. M. Menopausal estrogen therapy and hip fractures. Ann Intern Med. 1981 Jul;95(1):28–31. doi: 10.7326/0003-4819-95-1-28. [DOI] [PubMed] [Google Scholar]
  61. Paganini-Hill A., Ross R. K., Henderson B. E. Postmenopausal oestrogen treatment and stroke: a prospective study. BMJ. 1988 Aug 20;297(6647):519–522. doi: 10.1136/bmj.297.6647.519. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Persson I., Adami H. O., Bergkvist L., Lindgren A., Pettersson B., Hoover R., Schairer C. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. BMJ. 1989 Jan 21;298(6667):147–151. doi: 10.1136/bmj.298.6667.147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Pfeffer R. I., Kurosaki T. T., Charlton S. K. Estrogen use and blood pressure in later life. Am J Epidemiol. 1979 Oct;110(4):469–478. doi: 10.1093/oxfordjournals.aje.a112828. [DOI] [PubMed] [Google Scholar]
  64. Prior J. C. Progesterone as a bone-trophic hormone. Endocr Rev. 1990 May;11(2):386–398. doi: 10.1210/edrv-11-2-386. [DOI] [PubMed] [Google Scholar]
  65. Prior J. C., Vigna Y. M., Schechter M. T., Burgess A. E. Spinal bone loss and ovulatory disturbances. N Engl J Med. 1990 Nov 1;323(18):1221–1227. doi: 10.1056/NEJM199011013231801. [DOI] [PubMed] [Google Scholar]
  66. Raffle A. E., Cooper C. Bone density screening for osteoporosis. Lancet. 1990 Jul 28;336(8709):242–242. doi: 10.1016/0140-6736(90)91763-z. [DOI] [PubMed] [Google Scholar]
  67. Riis B. J., Christiansen C., Johansen J. S., Jacobson J. Is it possible to prevent bone loss in young women treated with luteinizing hormone-releasing hormone agonists? J Clin Endocrinol Metab. 1990 Apr;70(4):920–924. doi: 10.1210/jcem-70-4-920. [DOI] [PubMed] [Google Scholar]
  68. Riis B. J., Rødbro P., Christiansen C. The role of serum concentrations of sex steroids and bone turnover in the development and occurrence of postmenopausal osteoporosis. Calcif Tissue Int. 1986 Jun;38(6):318–322. doi: 10.1007/BF02555743. [DOI] [PubMed] [Google Scholar]
  69. Ross P. D., Wasnich R. D., Vogel J. M. Detection of prefracture spinal osteoporosis using bone mineral absorptiometry. J Bone Miner Res. 1988 Feb;3(1):1–11. doi: 10.1002/jbmr.5650030103. [DOI] [PubMed] [Google Scholar]
  70. Ross R. K., Paganini-Hill A., Gerkins V. R., Mack T. M., Pfeffer R., Arthur M., Henderson B. E. A case-control study of menopausal estrogen therapy and breast cancer. JAMA. 1980 Apr 25;243(16):1635–1639. [PubMed] [Google Scholar]
  71. Ross R. K., Paganini-Hill A., Mack T. M., Arthur M., Henderson B. E. Menopausal oestrogen therapy and protection from death from ischaemic heart disease. Lancet. 1981 Apr 18;1(8225):858–860. doi: 10.1016/s0140-6736(81)92138-3. [DOI] [PubMed] [Google Scholar]
  72. Selby P. L., Peacock M., Barkworth S. A., Brown W. B., Taylor G. A. Early effects of ethinyloestradiol and norethisterone treatment in post-menopausal women on bone resorption and calcium regulating hormones. Clin Sci (Lond) 1985 Sep;69(3):265–271. doi: 10.1042/cs0690265. [DOI] [PubMed] [Google Scholar]
  73. Sharf M., Oettinger M., Lanir A., Kahana L., Yeshurun D. Lipid and lipoprotein levels following pure estradiol implantation in post-menopausal women. Gynecol Obstet Invest. 1985;19(4):207–212. doi: 10.1159/000299035. [DOI] [PubMed] [Google Scholar]
  74. Slemenda C. W., Hui S. L., Longcope C., Wellman H., Johnston C. C., Jr Predictors of bone mass in perimenopausal women. A prospective study of clinical data using photon absorptiometry. Ann Intern Med. 1990 Jan 15;112(2):96–101. doi: 10.7326/0003-4819-112-2-96. [DOI] [PubMed] [Google Scholar]
  75. Smith D. M., Khairi M. R., Johnston C. C., Jr The loss of bone mineral with aging and its relationship to risk of fracture. J Clin Invest. 1975 Aug;56(2):311–318. doi: 10.1172/JCI108095. [DOI] [PMC free article] [PubMed] [Google Scholar]
  76. Veldhuis J. D., Gwynne J. T. Estrogen regulates low density lipoprotein metabolism by cultured swine granulosa cells. Endocrinology. 1985 Oct;117(4):1321–1327. doi: 10.1210/endo-117-4-1321. [DOI] [PubMed] [Google Scholar]
  77. Walker A. M., Jick H., Hunter J. R., Danford A., Watkins R. N., Alhadeff L., Rothman K. J. Vasectomy and non-fatal myocardial infarction. Lancet. 1981 Jan 3;1(8210):13–15. doi: 10.1016/s0140-6736(81)90116-1. [DOI] [PubMed] [Google Scholar]
  78. Walsh B. W., Schiff I., Rosner B., Greenberg L., Ravnikar V., Sacks F. M. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med. 1991 Oct 24;325(17):1196–1204. doi: 10.1056/NEJM199110243251702. [DOI] [PubMed] [Google Scholar]
  79. Wasnich R. D., Ross P. D., Heilbrun L. K., Vogel J. M. Prediction of postmenopausal fracture risk with use of bone mineral measurements. Am J Obstet Gynecol. 1985 Dec 1;153(7):745–751. doi: 10.1016/0002-9378(85)90338-2. [DOI] [PubMed] [Google Scholar]
  80. Weinstein M. C., Schiff I. Cost-effectiveness of hormone replacement therapy in the menopause. Obstet Gynecol Surv. 1983 Aug;38(8):445–455. doi: 10.1097/00006254-198308000-00001. [DOI] [PubMed] [Google Scholar]
  81. Weiss N. S., Ure C. L., Ballard J. H., Williams A. R., Daling J. R. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. N Engl J Med. 1980 Nov 20;303(21):1195–1198. doi: 10.1056/NEJM198011203032102. [DOI] [PubMed] [Google Scholar]
  82. Whitehead M. I., Townsend P. T., Pryse-Davies J., Ryder T., Lane G., Siddle N. C., King R. J. Effects of various types and dosages of progestogens on the postmenopausal endometrium. J Reprod Med. 1982 Aug;27(8 Suppl):539–548. [PubMed] [Google Scholar]
  83. Whitehead M., Lobo R. A. Consensus conference: Progestagen use in postmenopausal women. Lancet. 1988 Nov 26;2(8622):1243–1244. doi: 10.1016/s0140-6736(88)90824-0. [DOI] [PubMed] [Google Scholar]
  84. Windler E. E., Kovanen P. T., Chao Y. S., Brown M. S., Havel R. J., Goldstein J. L. The estradiol-stimulated lipoprotein receptor of rat liver. A binding site that membrane mediates the uptake of rat lipoproteins containing apoproteins B and E. J Biol Chem. 1980 Nov 10;255(21):10464–10471. [PubMed] [Google Scholar]
  85. Wingo P. A., Layde P. M., Lee N. C., Rubin G., Ory H. W. The risk of breast cancer in postmenopausal women who have used estrogen replacement therapy. JAMA. 1987 Jan 9;257(2):209–215. [PubMed] [Google Scholar]
  86. Wren B. G., Brown L. B., Routledge D. A. Differential clinical response to oestrogens after menopause. Med J Aust. 1982 Oct 2;2(7):329–332. doi: 10.5694/j.1326-5377.1982.tb132453.x. [DOI] [PubMed] [Google Scholar]
  87. Ziel H. K., Finkle W. D. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med. 1975 Dec 4;293(23):1167–1170. doi: 10.1056/NEJM197512042932303. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES